Satoris Solution: Biomarkers for Alzheimer’s Disease

Until now, no one has developed an Alzheimer's disease (AD) biomarker test that is:

• Highly specific and sensitive (>80%)1
• Predictive of earliest stages of disease1
• Non-invasive, reliable, reproducible, and simple to perform¹

Figure 1: The Satoris biomarker discovery process (Nature Medicine, November 2007).

In response to this need, Satoris has demonstrated a simple blood test that uses 18 protein biomarkers to identify AD and Mild Congnitive Impairment (MCI) that will progress to AD.

The results of a blind study on the Satoris test were published in Nature Medicine, October 2007. In that study, 259 samples were analyzed and the Satoris test was shown to be ~90% accurate in diagnosing AD versus normal subjects, as well as ~90% accurate in distinguishing AD from other dementias.

Figure 2: Identifying Alzheimer's Disease and discriminating Alzheimer's disease from other dementias.

Figure 3: Early identification of Alzheimer's disease in at-risk MCI patients.

To date, over 3,000 samples have been analyzed in the course of identifying and developing panels of Alzheimer’s related biomarkers.

Satoris is identifying, validating, and applying panels of protein biomarkers to a range of analytical platforms, with demonstrated utility in Alzheimer’s research and drug development, in Alzheimer’s clinical trial stratification and monitoring, and ultimately, in the diagnosis and management of Alzheimer’s patients.

¹Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease.” The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association, Chicago, IL and the National Institute on Aging, Bethesda, MD.